CClinicalTrials.gg
Sign In
Active, not recruitingNCT06189183Updated Jun 16, 2026

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

An interventional study of Adjuvant Hypofractionation Radiotherapy in Thymus Neoplasms, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

Read the detailed description

Adjuvant Radiotherapy(Postoperative radiotherapy) is proposed in stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.

Hypofractionation Radiotherapy is used in this study. The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

02

Conditions studied

  • Thymus Neoplasms

Browse trials for

Keywords

  • Thymus Neoplasms
  • Adjuvant Radiotherapy
03

In context

Thymus Neoplasms

89 studies on the registry are indexed under Thymus Neoplasms; 22 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 66 interventional studies indexed under Thymus Neoplasms.

Browse Thymus Neoplasms studies →

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 373 studies on the registry; 270 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Thymoma and Thymic carcinoma confirmed by histology or cytology
  • R0 resection (complete resection)
  • stage II and III thymic carcinoma，stage III thymoma，stage IIB B2/B3 thymomas.
  • Karnofsky performance status(KPS) 80, 90 or 100.
  • Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count>1.5×109 /L, platelet count>80×109 /L, hemoglobin ≥10g/dL.

Exclusion criteria

Exclusion Criteria:

  • Prior thoracic radiotherapy.
  • Uncontrolled Comorbidities.
  • Pregnant or nursing mother.
  • Pneumonia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Adjuvant Hypofractionation Radiotherapy

    Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

    Radiation: Adjuvant Hypofractionation Radiotherapy

Interventions

  • RadiationAdjuvant Hypofractionation Radiotherapy

    Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

06

What researchers measure

Primary outcomes

  1. Disease Free Survival

    From the date of resection to the date of disease recurrence or death

    Time frame: 2 years, 5 years

Secondary outcomes

  1. Overall Survival

    From the date of resection to the date of death

    Time frame: 2 years, 5 years

  2. RadiotherapyToxicity

    Rate of pneumonitis；Rate of esophagitis；Rate of skin reaction；Rate of myelitis；Rate of heart disease；Rate of vascular toxicity

    Time frame: 1 years, 2 years, 5 years

  3. local recurrence

    recurrence of tumor bed

    Time frame: 2 years, 5 years

  4. Intrathoracic recurrence / pleural metastasis

    Rate of Intrathoracic recurrence / pleural metastasis

    Time frame: 2 years, 5 years

  5. metastasis free survival

    From the date of resection to the date of metastasis or death

    Time frame: 2 years, 5 years

07

Study locations

1 site
  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
    Beijing, Beijing Municipality 100021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06189183
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Nov 11, 2023
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Jun 16, 2026

Study contacts

Tao Zhang, Dr.
principal investigator · National Cancer Center/Cancer Hospital, CAMS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thymus Neoplasms→

Other studies from this sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Start the discussion